Administrative, technical or material support: all authors
C., Phillips, R
The abdominal area is the preferred injection site, avoiding 1 to 2 inches around the navel, although some patients prefer injecting in the thighs or deltoids
Strategies to minimize immunogenicity include careful peptide design to maintain similarity to natural sequences, appropriate formulation development, and monitoring for antibody formation during clinical development and post-market surveillance
Zepbound (tirzepatide), a dual GIP/GLP-1 agonist, enhances weight loss results by targeting two hormones
Semaglutide, the primary ingredient in many weight loss drugs, mimics the natural GLP-1 hormone, promoting satiety and aiding in blood glucose regulation